Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome

Aurelio Negro, Giovanni M. Rossi, Davide Nicoli, Annibale Versari, Enrico Farnetti, Rosaria Santi, Stefano De Pietri

Research output: Contribution to journalArticle

Abstract

Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.

Original languageEnglish
JournalAmerican Journal of Kidney Diseases
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Gitelman Syndrome
Peptide Receptors
Radioisotopes
Kidney
Molecular Targeted Therapy
Somatostatin Receptors
Hypokalemia
Hypocalcemia
Therapeutics
Somatostatin
Electrolytes
Cardiac Arrhythmias
Urine
Radiation
Peptides
Serum

Keywords

  • 177-Lu-DOTATATE
  • Cancer
  • Case report
  • Gitelman
  • Hypocalcemia
  • Hypokalemia
  • Hypomagnesemia
  • Nephrotoxicity
  • Neuroendocrine tumors (NETs)
  • Peptide receptor radionuclide therapy (PRRT)
  • Radiometabolic
  • Tubulopathy
  • Urine electrolytes

ASJC Scopus subject areas

  • Nephrology

Cite this

Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome. / Negro, Aurelio; Rossi, Giovanni M.; Nicoli, Davide; Versari, Annibale; Farnetti, Enrico; Santi, Rosaria; De Pietri, Stefano.

In: American Journal of Kidney Diseases, 2017.

Research output: Contribution to journalArticle

@article{5dfda8c59e314cf49d56f9cbbfa0e424,
title = "Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome",
abstract = "Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.",
keywords = "177-Lu-DOTATATE, Cancer, Case report, Gitelman, Hypocalcemia, Hypokalemia, Hypomagnesemia, Nephrotoxicity, Neuroendocrine tumors (NETs), Peptide receptor radionuclide therapy (PRRT), Radiometabolic, Tubulopathy, Urine electrolytes",
author = "Aurelio Negro and Rossi, {Giovanni M.} and Davide Nicoli and Annibale Versari and Enrico Farnetti and Rosaria Santi and {De Pietri}, Stefano",
year = "2017",
doi = "10.1053/j.ajkd.2017.05.024",
language = "English",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome

AU - Negro, Aurelio

AU - Rossi, Giovanni M.

AU - Nicoli, Davide

AU - Versari, Annibale

AU - Farnetti, Enrico

AU - Santi, Rosaria

AU - De Pietri, Stefano

PY - 2017

Y1 - 2017

N2 - Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.

AB - Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.

KW - 177-Lu-DOTATATE

KW - Cancer

KW - Case report

KW - Gitelman

KW - Hypocalcemia

KW - Hypokalemia

KW - Hypomagnesemia

KW - Nephrotoxicity

KW - Neuroendocrine tumors (NETs)

KW - Peptide receptor radionuclide therapy (PRRT)

KW - Radiometabolic

KW - Tubulopathy

KW - Urine electrolytes

UR - http://www.scopus.com/inward/record.url?scp=85025142469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025142469&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2017.05.024

DO - 10.1053/j.ajkd.2017.05.024

M3 - Article

AN - SCOPUS:85025142469

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

ER -